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Signal transductionAldosterone is now recognised as an important actor in inﬂammation processes. Neoangiogenesis plays a
crucial role in this complex process and immune cells, such as neutrophils, appear to be able to secrete
different forms of (pro)angiogenic molecules, especially VEGF-A. The present work was undertaken to
investigate whether aldosterone was able to regulate VEGF-A production in human neutrophils. The HL-60
(progranulocytic) cell line and human polymorphonuclear leukocytes were incubated for different time
periods with aldosterone. Total cellular RNA extraction, submitted to reverse transcription and real time semi-
quantitative PCR, was used to study VEGF-A mRNA expression. Cell supernatants were collected and ELISA
tests were performed to analyse VEGF-A protein production. Aldosterone increased VEGF-A mRNA and
protein expression in a dose- and time-dependent manner in both cell types. Inhibitors of PI3 kinases, ERK1/2,
and to a lesser extent of p38 MAPK, decreased this aldosterone-induced immune cell activation. Western-blot
performed with HL-60 cells conﬁrmed that ERK1/2 and p38 MAPK pathways were stimulated by aldosterone.
Mineralocorticoid receptors are implicated in this VEGF-A up-regulation because HL-60 cells pre-treated with
spironolactone, an aldosterone receptor antagonist, diminished the effects of aldosterone. Aldosterone was
also able to increase VEGF-A production of phagocytic cells such as neutrophils. These results suggest that this
hormone could play an active role in the neovascularisation process by favouring entry of plasma proteins and
ﬂuids into the vascular wall, cell proliferation and tissue rebuilding.ré, Faculty of Medicine, 9 av de
ncy Cédex, France. Tel.: +33
rs).
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Accumulating evidence suggests that aldosterone is not only
implicated in water, potassium and sodium regulation homeostasis
but also possesses inﬂammatory propertieswhen produced in excess. In
animalmodels, direct hypertrophic and ﬁbrotic effects of aldosterone in
organs such as the heart and kidney have been reported and its
antagonists can counteract these deleterious effects [1–4]. In humans,
different studies have demonstrated that mineralocorticoid receptor
blockers like spironolactone or eplerenone diminished considerably
morbidity and mortality after myocardial failure [5,6]. Over the past
decade, numerous data have shown that aldosterone could play an
active role in vascular inﬂammation and remodelling. Attenuation of
atherosclerosis development by mineralocorticoid blockers has been
described [7,8]. Aldosterone causes endothelial cell dysfunction, in-
creases ICAM-1 [9,10], and promotes leukocyte adhesion to endothelial
cells and thence their inﬁltration [11,12]. In smooth muscle cells,
aldosterone increases NADPH oxidase activity and promotes theirproliferation [13,14]. In a mice ischemic hindlimb model, Michel et al.
have demonstrated that aldosterone increased vessel density in the
setting of ischemia and that this phenomenon implicatedMRactivation,
angiotensin and VEGF [15]. In mouse vessels with endothelial damage
and in human vessels from patients with atherosclerosis, aldosterone
enhances placental growth factor (PGF) expression, a member of the
VEGF family known to promote vascular cell proliferation and
inﬂammation [16]. Although an abundant literature exists for aldoster-
one's actions in non-immune cells, in comparison little is known for
leukocytes which are implicated in all steps of inﬂammation. Aldoste-
rone increases monocyte/macrophage oxidative metabolism and
integrin levels [17,18]. In murine models of vascular damage induced
by deoxycorticosterone/salt treatment or L-NAME/angiotensin II,
selective deletion of mineralocorticoid receptors from macrophages
protects the animals against cardiac hypertrophy, ﬁbrosis, remodelling
and increased systolic blood pressure [19,20]. Recently, it has been
described that the neutrophil, another immune cell, possesses miner-
alocorticoid receptors [21]. This cell plays a key role in inﬂammation
because they are the ﬁrst to inﬁltrate massively and rapidly phagocyte
pathogens and/or dead cells in case of tissue injury. Moreover, they
recruit monocytes and lymphocytes by chemokines, leukotriene B4
secretion and promote their diapedesis by pro-inﬂammatory cytokine
release [22]. Optimal leukocyte recruitment and coordination will be
crucial for tissue repair and inﬂammation resolution. Neoangiogenesis
2126 C. Walczak et al. / Biochimica et Biophysica Acta 1813 (2011) 2125–2132constitutes an important part of this complex process and neutrophils
are a rich source of released (pro)angiogenicmolecules.Members of the
vascular endothelial growth factor (VEGF) family, notably VEGF-A,
stimulate strongly endothelial cell migration and proliferation. More-
over, they induce neutrophil, monocyte/macrophage and smooth
muscle cell chemotaxis, mediate increased microvascular permeability,
facilitate neutrophil adhesion to endothelial cells and their transmigra-
tion [23–26]. Different cells, such as monocytes and neutrophils, are
able to secrete large amounts of VEGF-A, one of the most powerful
angiogenic molecules [27].
Since angiogenesis and immune cells are intimately implicated in
inﬂammation and tissue repair, we investigated whether neutrophils
treated with aldosterone could increase their VEGF-A production and
consequently could induce a proangiogenic phenotype.Wehave shown
that aldosterone increases VEGF-A mRNA and protein expression in
human neutrophils and granulocyte-differentiated HL-60 cells. This
upregulation required activation of PI3kinase, ERK1/2, and, to a lesser
extent, p38MAPKpathways. Spironolactone, an aldosterone antagonist,
was able to diminish signiﬁcantly the effects of aldosteroneon increased
VEGF-A production.2. Materials and methods
2.1. Reagents
Aldosterone, spironolactone, DMSO, transduction signal inhibitors
(Ly294002, PD98059, SB203580), actinomycin and cycloheximide
were purchased from Sigma-Aldrich (L'Isle d'Abeau Chesnes, France).A
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Fig. 1. Aldosterone increases VEGF-A mRNA levels in HL-60 cells and in neutrophils in a dose
were puriﬁed with Polymorphprep solution. For both cell types, after aldosterone (Aldo) incu
real time PCR were carried out with speciﬁc primers for RPS-29 and VEGF-A. The results are e
three separate experiments. Arbitrary units were used and the mean value of 1 was attribute
error bars are S.D. and “⁎”represents a signiﬁcant difference (Pb0.05) between control and
10−9 M, and $Pb0.05 aldosterone at 10−8 M vs aldosterone at 10−9 M. (B): Ratios of VEGF
signiﬁcant difference (Pb0.05) between control and aldosterone-treated cells, £Pb0.05 aldo2.2. Cell culture and treatments
The human progranulocytic cell line, HL-60, was cultured at 37 °C
under 5% CO2 in RPMI 1640 medium containing 10% heat inactivated
foetal calf serum (Eurobio, Courtaboeuf, France), 100 U/mL penicillin,
100 μg/mL streptomycin, 10 mM Hepes, 2 mM L-glutamine, 1 mM
sodium pyruvate (all purchased from Sigma-Aldrich), and 1× non
essential amino-acids (Gibco-BRL, Invitrogen, Baisley, UK). To differ-
entiate HL-60 cells into the neutrophil-lineage, dimethylsulfoxide
(DMSO) 1.3% was added to the cell culture medium over three days,
followed by three days with DMSO at 0.65% [28]. Polymorphonuclear
leukocytes were collected from blood of ﬁve human volunteers and
puriﬁed with the Polymorphprep method (Abcys, Paris, France).
These cells were then cultured under the same conditions as for the
HL-60 cells and FACS experiments revealed a purityN96%. The HL-60
cells and neutrophils were incubated for different time periods with
aldosterone (Aldo) at 10−7, 10−8, 10−9 M. At the beginning of all
kinetics, cellular density was 0.8106 cells/mL. Cell viability in the
presence or absence of inhibitors was measured by cell counting with
Trypan blue and by Annexin V assays. For experiments with inhibitors
(all solubilised with DMSO), aldosterone at 10−7 M served as the
control and was compared to “aldosterone at 10−7 M+DMSO”.
Inhibitors were always added 30 min before aldosterone.2.3. Real time semi-quantitative PCR
Total RNA was extracted from cultured cells using Trizol reagent
(Euromedex, Mundolsheim, France). For cDNA synthesis, 2 μg of totalh 6h 24h
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- and time-dependent manner. Neutrophils provided from blood of healthy volunteers
bation for different time periods, RNA extraction, cDNA synthesis and semi-quantitative
xpressed as ratios of VEGF-A mRNA/RPS-29 mRNA and representative of a minimum of
d to the duration 0 min. (A): Ratios of VEGF-A mRNA/RPS-29 mRNA in HL-60 cells. The
aldosterone-treated cells, £Pb0.05 aldosterone at 10−7 M vs aldosterone at 10−8 M,
-A mRNA/RPS-29 mRNA in neutrophils. The error bars are the S.D. and “⁎”represents a
sterone at 10−7 M vs aldosterone at 10−8 M.
2127C. Walczak et al. / Biochimica et Biophysica Acta 1813 (2011) 2125–2132RNA was retrotranscribed with 40 units of Mu-MLV (MBI Fermentas,
Euromedex), 2 mM dNTP (MBI Fermentas), 0.25 μM oligo dT15
(Invitrogen), RT 1× buffer, 10 units of RNAse inhibitor (MBI Fermentas)
during 1 h at 37 °C. Oligonucleotide sequences used to amplify VEGF-A
(GenBank accession number AF022375) were respectively [29]: sense
5′-ggagggcagaatcatcacgaag-3′ and antisense 5′-cacacaggatggcttgaa-
gatg-3′. For RPS-29 (GenBank accession number NM001032) oligonu-
cleotide sequences were: sense 5′-aag atg ggt cac cag cag ctg tac tg-3′
and antisense 5′-aga cac gac aag agc gag aa-3′. PCR conditions were as
follows: activation for 3 min at 95 °C, 40 cycles of ampliﬁcation for 10 s
at 95 °C, 45 s at 58 °C (VEGF-A) or 60 °C(RPS-29) followed by 1 min at
95 °C, 1 min at 55 °C and then 80 cycles of 10 s at 55 °C. VEGF-A mRNA
levels were normalised to those of RPS-29 mRNA levels.
2.4. Measurement of total VEGF-A by ELISA
After 24 h in culture, HL-60 cell and neutrophil supernatants were
centrifuged to remove any dead cells. VEGF-A concentrations were0
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Fig. 2. Aldosterone increasesVEGF-AmRNA levels in a PI3K, ERK1/2 andp38dependent pathwa
protein synthesis. HL-60 cells andneutrophilswerepreincubated for 30 min at 37 °Cwith PD980
DMSO (solvent) and then stimulated with aldosterone at 10−7 M for different time periods.
synthesis inhibitor) were tested on HL-60 cells. All inhibitors were used at the same concentra
RNA extraction 30 min, 1 h 30 min, 3 h, 6 h, and 24 h after aldosterone addition. cDNA synthe
Results are expressed as ratios of VEGF-AmRNA/RPS-29mRNA and are representative of aminim
was attributed to the duration 0 min. (A, B): Ratios of VEGF-AmRNA/RPS-29mRNA in HL-60 ce
control and aldosterone-treated cells, $Pb0.05 vs DMSO+aldosterone at 10−7 M. (C): Ratios o
“⁎”represents a signiﬁcant difference (Pb0.05) between control and aldosterone-treated cells,determined by enzyme-linked immunosorbent assay with VEGF-A
kits (R&D Systems, Lille, France). Assays were performed as
recommended by the manufacturer's protocol and experiments
were duplicated and repeated three to ﬁve times each.
2.5. Protein analysis and quantiﬁcation
Cells were lysed with cell lysis buffer (Cell Signaling Technology,
Beverly, USA) and extraction was performed in the presence of a
complete protease inhibitor mixture (Roche Molecular Biochemicals,
Mannheim, Germany). Protein concentrations were determined by a
DC protein assay (Bio-Rad).
2.6. Western blotting analysis
Equal amounts of protein were subjected to electrophoresis on a
SDS–polyacryamide gel (Bio-Rad) and transferred onto polyvinyli-
dene diﬂuoride membranes (Millipore, Molsheim, France). After6h 24h
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y inHL-60 cells and inneutrophils. This up-regulation requires for a part a denovoRNA and
59, aMEK1 inhibitor, Ly290042, a PI3K inhibitor, SB203580, a p38MAPK inhibitor, orwith
Two other inhibitors, cycloheximide (protein synthesis inhibitor) or actinomycin (RNA
tion (10 μM) except actinomycin (0.01 μg/mL). For both cell types, cells were collected for
sis and semi-quantitative real time PCR with RPS-29 and VEGF-A primers were realised.
umof three independent experiments. Arbitrary unitswere used and themeanvalue of 1
lls. The error bars are the S.D. and “⁎”represents a signiﬁcant difference (Pb0.05) between
f VEGF-AmRNA/RPS-29mRNA in polymorphonuclear cells. The error bars are the S.D. and
$Pb0.05 vs DMSO+aldosterone at 10−7 M.
**
*
*
*
$
$
$ $
$£
£
£
£
£
*
*
*
*
£
£
$
*
B
A160
140
120
100
80
60
40
20
0
160
140
120
100
80
60
40
20
0
VE
G
F-
A 
pr
ot
ei
n 
(pg
/m
L)
VE
G
F-
A 
pr
ot
ei
n 
(pg
/m
L)
Control
Control
Aldo at 10-8MAldo at 10-9M Aldo at 10-7M
Aldo at 10-7M
Aldo at 10-7M + DMSO
Aldo at 10-7M + PD98059
Aldo at 10-7M + Ly294002
Aldo at 10-7M + SB203580
Aldo10-7M+actinomycin
Aldo10-7M+cycloheximide
Fig. 3. Aldosterone increases VEGF-A protein release in HL-60 cell culture supernatants in
a concentration- dependent manner. The PI3K, MEK1/2 inhibitors and, to a lesser extent
p38 inhibitor, block this up-regulation. This phenomenon depends partially of a de novo
RNA and protein synthesis. (A): HL-60 cells were stimulated with aldosterone at 10−7,
10−8 or 10−9 M and culture supernatants were collected 24 h later for ELISA tests. This
experimentwas repeated in duplicate three toﬁve times. The bars are the S.D. and Pb0.05
was considered as signiﬁcant. ⁎Pb0.05 vs control, £Pb0.05 vs aldosterone at 10−7 M and
$Pb0.05 vs aldosterone at 10−8 M. (B): HL-60 cells were pre-treated with an inhibitor
(10 μM each except actinomycin at 0.01 μg/mL) for 30 min at 37 °C and then incubated
with aldosterone at 10−7 M. Culture supernatants were recovered 24 h later for ELISA
tests. Data are presented as themean±S.D. of experiments repeated independently three
to ﬁve times in duplicate. ⁎Pb0.05 vs control, £Pb0.05 vs aldosterone at 10−7 M, $Pb0.05
vs DMSO+aldosterone at 10−7 M.
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Fig. 4. Aldosterone upregulates VEGF-A protein excretion in neutrophil culture
supernatants in a concentration-dependent manner and requires the activation of
the PI3K, ERK1/2 and p38 dependent pathways. Neutrophils were incubated with
aldosterone and inhibitors in the same conditions as for HL-60 cells. Data are presented
as the mean±S.D. of experiments repeated independently three to ﬁve times in
duplicate. ⁎Pb0.05 vs control, £Pb0.05 vs aldosterone 10−7 M, $Pb0.05 vs DMSO+
aldosterone at 10−7 M.
2128 C. Walczak et al. / Biochimica et Biophysica Acta 1813 (2011) 2125–2132blocking, membranes were incubated with an anti-phospho ERK 1/2
or an anti-phospho p38 MAPK rabbit antibody (Cell Signaling
Technology). Membranes were washed and incubated with an anti-
rabbit IgG-peroxidase conjugate (Jackson immunolaboratories, West
Grove, USA). To determine the amounts of phosphorylated ERK 1/2 or
p38 MAPK, blots were stripped and reprobed using respectively an
anti-total ERK1/2 or an anti-total p38 MAPK rabbit antibody (Cell
Signaling) followed with an anti-rabbit IgG-peroxidase conjugate
(Jackson immunolaboratories). Each membrane was subsequently
washed and immunocomplexes were visualised by chemilumines-
cence (LAS 4000 imager, Fuji, Bois d'Arcy, France). The signals were
analysed by densitometry (Multi-Gauge, Fuji).
2.7. Statistical and data analysis
All experiments were repeated a minimum of three times. All data
are given as mean±S.D and a Mann–Whitney U test was used. A
statistically signiﬁcant difference was set at Pb0.05.
3. Results
3.1. Effect of aldosterone on VEGF-A mRNA levels in HL-60 and in human
polymorphonuclear cells
HL-60 cells were incubated with aldosterone (Aldo) at 10−7, 10−8
or 10−9 M for different time periods. As shown in Fig. 1A, aldosterone
increased VEGF-AmRNA expression in HL-60 cells. This up-regulation
appeared as early as 30 min and reached a peak at 6 h whatever
aldosterone concentration used. At 6 h, VEGF-A mRNA levels had
increased approximately 9.75-fold with aldosterone at 10−7 M, 6.9-
fold with 10−8 M and 4.6-fold with 10−9 M compared to unstimu-
lated cells. This increase was also dose-dependent. Thus, aldosterone
up-regulates VEGF-A mRNA expression in HL-60 cells in a concentra-
tion- and time-dependent manner.
In order to verify that our results were not restricted to the HL-60
cells, human polymorphonuclear leukocytes were used. As shown in
Fig. 1B, aldosterone up-regulated VEGF-A mRNA in human neutro-
phils. This increase was time- and dose-dependent as for the HL-60
cells. Precisely, in the presence of aldosterone at 10−7 M, VEGF-A
mRNA peaked at approximately 6 h and was of 7.7-fold compared to
untreated polymorphonuclear cells. This phenomenon was concen-
tration-dependent since with aldosterone at 10−8 M, the increase
was only 4.5-fold. Thus, in human neutrophils, VEGF-A mRNA up-
regulation mediated by aldosterone was time- and dose-dependent,
as observed for the HL-60 cells.
3.2. Effects of different inhibitors on VEGF-A mRNA increase induced by
aldosterone
The putative transduction signal pathways used by aldosterone to
induce this VEGF-A mRNA up-regulation were further investigated.
HL-60 cells were pre-incubated with inhibitors (all at 10 μM) or their
solvent (DMSO) and 30 min after, aldosterone at 10−7 M was added.
Eventual effects of inhibitors and DMSO on cell viability and on VEGF-
A mRNA expression were respectively tested by Annexin V assays and
real time PCR. At the concentrations used, neither inhibitor nor DMSO
had a signiﬁcant inﬂuence on cell death and on VEGF-A mRNA
expression (data not shown). Pre-treatment with Ly294002, a PI3K
inhibitor, or with PD98059, a MEK1 inhibitor, attenuated signiﬁcantly
aldosterone-increased VEGF-A mRNA (Pb0.05; Fig. 2A). With
SB203580, a p38 inhibitor, this inhibition was also signiﬁcant but
less pronounced compared with ERK1/2 and PI3K inhibition (Fig. 2A).
In fact, the increase in VEGF-AmRNA expression, 6 h after aldosterone
addition, was only 2.2-fold in the presence of Ly294002, 4.3-fold with
PD98059 and 6-fold with SB203580, instead of 9.75-fold observed
with aldosterone at 10−7 M alone (Fig. 2A).Thereafter,we studied aneventual requirement of denovoRNAand/
or protein synthesis for this VEGF-A mRNA up-regulation. Pre-
incubation with actinomycin at 0.01 μg/mL, an RNA synthesis inhibitor,
or with cycloheximide at 10 μM, a protein synthesis inhibitor decreased
signiﬁcantly VEGF-A mRNA up-regulation orchestrated by aldosterone.
Pre-incubated cells increased their VEGF-A mRNA approximately 3.5-
fold for both inhibitors compared to 9.75-fold with aldosterone at
10−7 M alone (Fig. 2B). Thus, aldosterone increased VEGF-A mRNA
levels in HL-60 cells via a PI3K, ERK1/2 and p38 dependent-activation
pathway. Moreover, this phenomenon appeared to need de novo RNA
and protein synthesis.
2129C. Walczak et al. / Biochimica et Biophysica Acta 1813 (2011) 2125–2132As VEGF-A mRNA up-regulation orchestrated by aldosterone was
shared by the HL-60 line and polymorphonuclear cells, we examined
if the transduction signal pathwayswere also preserved between both
cell types. Neutrophils were incubated with inhibitors or DMSO and
30 min after, aldosterone was added, as for the HL-60 cells. Pre-
treatment of neutrophils with Ly294002, PD98059 or SB203580
diminished signiﬁcantly the aldosterone-induced VEGF-AmRNA level
increase (Fig. 2C). More precisely, 6 h after hormone addition, VEGF-A
mRNA increased expression by aldosterone at 10−7 M in the presence
of Ly294002 was only 2.5-fold, 3.2-fold with PD98059 and 4.8-fold
with SB203580, compared with 7.7-fold obtained with aldosterone at
10−7 M (Fig. 2C). Thus, in polymorphonuclear cells, aldosterone
upregulated VEGF-A mRNA in a PI3K, ERK1/2 and p38 kinase-
dependent manner as for HL-60 cells.
3.3. Effect of aldosterone on VEGF-A protein expression in HL-60 cells
HL-60 cells were treated with aldosterone at 10−7, 10−8 or
10−9 M and cell culture supernatants were collected 24 h later. ELISA
tests were performed to analyse total VEGF-A. On average, untreated
cells released 56 pg/mL (±11.5) of VEGF-A for 0.8 106 cells/mL. In the
presence of aldosterone at 10−7 M, VEGF-A protein concentration
was 131.5 pg/mL (±13; 2.33-fold). Aldosterone used at 10−8 or
10−9 M increased VEGF-A protein production, respectively 1.9-fold
(108.4 pg/mL±13.3) and 1.7-fold (98.6 pg/mL±10), compared to
untreated cells (Fig. 3A). Thus, as for VEGF-A mRNA, VEGF-A protein
level up-regulation by aldosterone was concentration-dependent.
We focused on the signalling pathways used by aldosterone to
increase VEGF-A protein in cell culture supernatants. HL-60 cells were
pre-treated with Ly294002, PD98059, or SB203580 transduction
signal inhibitors (10 μM each) or DMSO and 30 min after, aldosterone
at 10−7 M was added as for the VEGF-A mRNA experiments. Cell
culture supernatants were taken out 24 h later for VEGF-A ELISA tests.
HL-60 cells pre-treatment with these inhibitors decreased aldoste-
rone-induced VEGF-A protein expression. VEGF-A protein production
enhancement induced by DMSO+aldosterone at 10−7 M (126.9 pg/
mL±21) compared to control (56 pg/mL±11.5) was strongly
diminished in the presence of these inhibitors: namely 63.9 pg/mL
(±11.1) with Ly294002, 78.2 pg/mL (±11) with PD98059. The
increase in VEGF-A protein production was only attenuated signiﬁ-Total p38
p-p38
p-ERK-2
A
B
0 1h 2h 4h 6h 24h10min 0.5h
Total ERK-2
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Fig. 5. Effects of aldosterone on ERK1/2 and p38MAPK phosphorylation status in HL-60 cells.
centrifugation, cells were lysed and proteins were quantiﬁed. Total cell proteins were separ
and p38 MAPK was studied respectively by using an anti-phospho ERK-1/-2 and an anti-pho
relative changes in their phosphorylation status. To control protein loading, membranes we
MAPK rabbit antibody. (A): Phosphorylation of ERK 1/2 (p-ERK-1, -2) and its control “Total E
The experiment shown is representative of four independent experiments.cantly in the presence of SB203580 (102 pg/mL±19.5), (Fig. 3B).
Aldosterone activated PI3K, ERK 1/2 and p38 MAPK pathways to up-
regulate VEGF-A protein production in HL-60 cells.
Finally, we studied if this aldosterone-increased VEGF-A protein
expression in cell culture supernatants was due to de novo RNA and/
or protein synthesis. In the presence of actinomycin at 0.01 μg/mL and
in the presence of cycloheximide at 10 μM, the VEGF-A increase
mediated by aldosterone was reduced approximately by half
(respectively 76.6 pg/mL±19.5 and 60.6 pg/mL±12.1 compared to
126.9 pg/mL±21). Hence, this VEGF-A excretion was partly due to de
novo RNA and protein expression (Fig. 3B).
3.4. Effect of aldosterone on VEGF-A protein expression in human
polymorphonuclear cells
We further investigated if VEGF-A mRNA up-regulation by
aldosterone in neutrophils was followed by an enhanced VEGF-A
protein expression. We incubated these cells (0.8 106 cells/mL) with
aldosterone at 10−7 M or at 10−8 M during 24 h. Cells' supernatants
were used to realise VEGF-A ELISA tests. As shown in Fig. 4,
aldosterone was able to up-regulate neutrophil VEGF-A protein
release and this effect appeared concentration-dependent: 2.5-fold
with aldosterone at 10−7 M (63.8 pg/mL±10.6) and 1.7-fold with
aldosterone at 10−8 M (43 pg/mL±12.2) compared to untreated
neutrophils (25.5 pg/mL±6.9). Signal transduction inhibitors
(Ly294002, PD98059 and SB203580) added 30 min before aldoste-
rone at 10−7 M decreased VEGF-A protein excretion. In detail, with
Ly294002, the VEGF-A increase was only 1.3-fold (33 pg/mL±6.5)
compared to DMSO+aldosterone at 10−7 M (2.35-fold, 59.1 pg/mL±
18), with PD98059 a 1.47-fold (37.4 pg/mL±8) and with SB203580 a
1.88-fold (48 pg/mL±9.8) increase. Thus, aldosterone stimulated
VEGF-A protein excretion in neutrophils in a PI3K, ERK1/2 and p38
dependent pathway, as observed for HL-60 cells.
3.5. Analysis of the aldosterone stimulation pathway by Western-blot
To corroborate these ﬁndings, we analysed by Western blot the
ERK 1/2 and p38 MAPK phosphorylation status after aldosterone
addition. HL-60 cells were incubated with aldosterone at 10−7 M
during different time periods. Results presented in Fig. 5 show that0
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addition and peaked approximately 2 h later. A transient increase in
ERK1/2 phosphorylation was seen 2 min after aldosterone addition
(data not shown). For p38 MAPK, phosphorylation started approxi-
mately 15 min after hormone addition and ﬁnished approximately 2 h
later. Thus,Western blot analyseswere in agreementwith RT-PCR and
ELISA experiments.
3.6. Effect of spironolactone on VEGF-A mRNA and protein increase
induced by aldosterone in HL-60 cells
We used an aldosterone antagonist, spironolactone (Spiro), to
investigate if this molecule could counteract aldosterone effects on
VEGF-A upregulation. Spironolactone was used at 10−7 or 10−6 M on
HL-60 cells and 30 min later, aldosterone at 10−7 M was added. RNA
extraction was performed 6 h after aldosterone addition when the
VEGF-A mRNA peak occurred (Fig. 1). For VEGF-A protein analysis,
HL-60 cell culture supernatants were collected 24 h after. As shown in
Fig. 6A, spironolactone inhibited partially and dose-dependently the
aldosterone effects on VEGF-AmRNA and protein levels. Precisely, the
VEGF-A mRNA peak at 6 h was reduced approximately by half in the
presence of spironolactone at 10−7 M (5.6-fold vs 10.1-fold), and by
three quarters in the presence of spironolactone at 10−6 M (2.65-foldA
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Fig. 6. Effect of spironolactone on VEGF-AmRNA and protein upregulation orchestrated
by aldosterone. HL-60 cells were incubated with spironolactone (Spiro) at 10−6 M or
10−7 M and 30 min later aldosterone at 10−7 M was added or not to cell culture
medium. (A): For RNA analysis, 6 h after, HL-60 cells were lysed, RNAs were extracted,
reverse transcribed and submitted to semi quantitative real-time PCR. The results are
expressed as ratios of VEGF-A mRNA/RPS-29 mRNA and representative of a minimum
of three separate experiments. Arbitrary units were used and the mean value of 1 was
attributed to the duration 0 min. The error bars are S.D. and “⁎”represents a signiﬁcant
difference (Pb0.05) between control and aldosterone-treated cells, £Pb0.05 spirono-
lactone at 10−7 M+aldosterone at 10−7 M vs aldosterone at 10−7 M and $Pb0.05
spironolactone at 10−6 M+aldosterone at 10−7 M vs aldosterone at 10−7 M. (B): For
VEGF-A protein analysis, cell culture supernatants were taken out 24 h later after
aldosterone addition. The error bars are the S.D. and “⁎”represents a signiﬁcant
difference (Pb0.05) between control and aldosterone-treated cells, £Pb0.05 spirono-
lactone at 10−7 M+aldosterone at 10−7 M vs aldosterone at 10−7 M and $Pb0.05
spironolactone at 10−6 M+aldosterone at 10−7 M vs aldosterone at 10−7 M.vs 10.1-fold). At the VEGF-A protein level, this reduction was
respectively 28% (95.6 pg/mL±11.2 vs 131.5 pg/mL±13) and 42%
(77.7 pg/mL±10.8 vs 131.5 pg/mL±13); (Fig. 6B). Thus, aldosterone
uses mineralocorticoid receptors to enhance VEGF-A mRNA and
protein production in HL-60 cells.
4. Discussion
Over the past few years, it has become clear that aldosterone/
mineralocorticoid receptors possess hypertensive, ﬁbrotic effects and
can exert important inﬂammatory effects in the vasculature system
and in organs such as the kidneys and the heart. Moreover, different
data have demonstrated that the hormone exerts proangiogenic
effects on damaged vascular wall [15,16]. Immune cells are intimately
linked to all these phenomena and they communicate with stressed
vascular cells to repair the injured tissue. Nevertheless, little data exist
about aldosterone/mineralocorticoid receptors and leukocytes. The
purpose of our study was to investigate if aldosterone exerts a
potential proangiogenic role in leukocytes and especially in neutro-
phils which possess mineralocorticoid receptors and are present in
the altered tissue from the beginning to the inﬂammation resolution.
In fact, in this process angiogenesis plays a crucial role in tissue
regeneration. Neutrophils are able to produce different (pro)angio-
genic molecules, notably VEGF-A in large amounts. We therefore
investigated if aldosterone was able to affect neutrophil VEGF-A
production. We were thus able to demonstrate that aldosterone up-
regulates VEGF-A production in the granulocyte-differentiated HL-60
cells and in human blood polymorphonuclear leukocytes. This cell line
constitutes also a good model for this type of study. This increase
occurred both at themRNA and at the protein level and was dose- and
time-dependent. For both cell types, the VEGF-A mRNA increase had
started by 30 min after aldosterone addition and peaked around 6 h
later. Twenty-four hours after, VEGF-A excretion was still increased in
cell culture supernatants. Studies with transduction signal inhibitors
demonstrated that PI3K and ERK1/2 activation pathways were
implicated in this up-regulation and to a lesser extent the p38 MAP
kinase pathway. Western-blotting analyses showed that ERK1/2 and
p38 MAPK pathways were activated. Nevertheless, ERK1/2 activation
seemed to be the most potent. Interestingly, this powerful ERK1/2
activation is shared by different cell types such as renal cells and
myocytes [30,31]. We have remarked that ERK1/2 activation was
biphasic: a ﬁrst activation at 2 min, fugacious, and a second which
began approximately 30 min after aldosterone addition and which
endured. The p38 MAP kinase activation pathway by aldosterone has
also been shown in myocytes and in smooth muscle cells [31,13]. As
these two pathways are activated, and for ERK1/2 on both occasions,
we cannot exclude that different events arise. For example, at ﬁrst,
mineralocorticoid receptors could be activated by aldosterone and
then superoxide anion and/or pro-inﬂammatory cytokines could be
released that in turn would activate cells by the bias of these MAP
kinase pathways. These molecules have been shown to activate
ERK1/2 and p38 MAPK pathways in neutrophils [32,33]. One other
possibility (which does not exclude the ﬁrst) is that in neutrophils, as
in other cells, epidermal growth factor and mineralocorticoid re-
ceptors could be colocalized at the plasma membrane and could be
able to transactivate signals [34]. An argument in favour of this is that
when transactivation occurs, the ERK1/2 pathway is activated. We
have shown that actinomycin and cycloheximide, respectively RNA
and protein synthesis inhibitors, diminished signiﬁcantly the VEGF-A
increase mediated by aldosterone but the inhibition was only partial.
As an increase in inhibitor concentration had consequences on cell
viability, we do not know if this VEGF-A upregulationwas due entirely
to de novo synthesis. It is possible that part of the released VEGF-A
comes from an increase in mRNA half-life, direct neutrophil
degranulation and/or membrane VEGF-A cleavage [35,36]. It should
be noted that a discrepancy exists in both cell types between the
2131C. Walczak et al. / Biochimica et Biophysica Acta 1813 (2011) 2125–2132VEGF-A mRNA rate increase (about ×10 at 6 h) and the excreted
VEGF-A protein rate (about ×2.5 at 24 h). Different possible
explanations exist: an important part of VEGF-A mRNA is non-
translated and/or neoformedVEGF-A proteins are stored in neutrophil
granules and/or remain bound to neutrophil membranes. Further, we
investigated an eventual requirement of mineralocorticoid receptors
on VEGF-A upregulation. The use of an aldosterone antagonist,
spironolactone, permitted us to show that the VEGF-A level increase
obtained with aldosterone in HL-60 cells was dose-dependently
diminished but not entirely abrogated in the presence of the
spironolactone. So, a non-negligible part of the VEGF-A increased
production is mediated by mineralocorticoid receptor activation.
Now, it remains to be determined if aldosterone is able to increase
other pro-angiogenic molecules like VEGF-C and/or VEGF-D which
can be produced by polymorphonuclear cells. Moreover, a number of
studies have demonstrated that aldosterone potentiates the angio-
tensin II-induced proinﬂammatory role now that neutrophils are
known to possess AT1 receptors [37]. Pupilli et al. have shown that
mesangial cells treated with angiotensin II enhanced their VEGF
production [38]. The study by Zhao et al. demonstrated the role of
VEGF in vascular inﬂammation mediated by angiotensin II [39]. More
recently, it has been reported that aldosterone needs angiotensin type
1a receptors to active signalling pathways in vascular smooth muscle
cells [40]. So, it will be very important to investigate if (and how)
angiotensin II exerts any effect on VEGF-A regulation, and whether or
not it cooperates with aldosterone in neutrophils. Other immune cells
such as monocytes/macrophages are also involved in wound healing,
inﬂammation and neoangiogenesis. They possess mineralocorticoid
receptors and produce large amounts of VEGF-A, so it will be
important to investigate if aldosterone is able to regulate also their
VEGF-A production.
In conclusion, we have shown that aldosterone, as well as being
implicated in different phenomena such as ﬂuid homeostasis, ﬁbrotic
andhypertrophic effects in organs, could also favourneoangiogenesis via
its effects on immune cells such as neutrophils. Aldosterone could play a
positive role by favouring immune cell adhesion and angiogenesis in
“normal” cases of tissue repair, and could promote neovessel uncon-
trolled growth in deleterious cases, detrimental to the organism.
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